share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(14.8%),Stockton Limited(14.8%), etc.

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(14.8%),Stockton Limited(14.8%), etc.

SC 13G/A：超過5%持股股東披露文件(修正)-Nirland Limited(14.8%),Stockton Limited(14.8%)等
美股SEC公告 ·  08/14 04:33

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. has been the subject of an amended Schedule 13G filing with the United States Securities and Exchange Commission (SEC), dated August 13, 2024. The amendment, which supplements the original filing from October 2, 2023, discloses that Nirland Limited, along with related entities Stockton Limited, The Rowland Master Trust, and Dovet Limited, collectively hold a 14.8% ownership stake in Conduit Pharmaceuticals. This stake amounts to 14,500,000 shares of common stock. The shares include 12,500,000 directly issued to Nirland Limited and an additional 2,000,000 shares potentially issuable upon the exercise of a common stock warrant. The entities are all registered in Guernsey and are interconnected through ownership and trust relationships, with Dovet Limited acting as the sole trustee of The Rowland Master Trust, which wholly owns Stockton Limited, which in turn owns Nirland Limited. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.
Conduit Pharmaceuticals Inc. has been the subject of an amended Schedule 13G filing with the United States Securities and Exchange Commission (SEC), dated August 13, 2024. The amendment, which supplements the original filing from October 2, 2023, discloses that Nirland Limited, along with related entities Stockton Limited, The Rowland Master Trust, and Dovet Limited, collectively hold a 14.8% ownership stake in Conduit Pharmaceuticals. This stake amounts to 14,500,000 shares of common stock. The shares include 12,500,000 directly issued to Nirland Limited and an additional 2,000,000 shares potentially issuable upon the exercise of a common stock warrant. The entities are all registered in Guernsey and are interconnected through ownership and trust relationships, with Dovet Limited acting as the sole trustee of The Rowland Master Trust, which wholly owns Stockton Limited, which in turn owns Nirland Limited. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.
Conduit Pharmaceuticals Inc.已經在2024年8月13日提交了一份修改後的13G申報表，該申報表同時補充了2023年10月2日的原始申報。修改後的申報表披露了Nirland Limited以及相關實體Stockton Limited、The Rowland Master Trust和Dovet Limited共同持有Conduit Pharmaceuticals的14.8%股權。這一股權相當於Conduit Pharmaceuticals的1450萬股普通股，其中1200萬股直接由Nirland Limited持有，另外還有200萬股股票可能在行使普通股認股證的情況下...展開全部
Conduit Pharmaceuticals Inc.已經在2024年8月13日提交了一份修改後的13G申報表，該申報表同時補充了2023年10月2日的原始申報。修改後的申報表披露了Nirland Limited以及相關實體Stockton Limited、The Rowland Master Trust和Dovet Limited共同持有Conduit Pharmaceuticals的14.8%股權。這一股權相當於Conduit Pharmaceuticals的1450萬股普通股，其中1200萬股直接由Nirland Limited持有，另外還有200萬股股票可能在行使普通股認股證的情況下發行。這些實體都註冊在根西島，通過所有權和信託關係相互關聯，其中Dovet Limited是The Rowland Master Trust的唯一受託人，後者完全擁有Stockton Limited，後者又擁有Nirland Limited。申報表指出這些股份的收購併非出於改變或影響Conduit Pharmaceuticals控制權的目的。

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Aptose Biosciences
    APTO
    -- 0.2790
    Prelude Therapeutics
    PRLD
    -- 1.300
    Aadi Biosciences
    AADI
    -- 3.390
    Abpro Holdings
    ABP
    -- 2.070
    Xilio Therapeutics
    XLO
    -- 1.280

    解鎖榜首股票